Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HTMC0435 with Temozolomide in SCLC
NCT05728619Phase 2Unknown
- Sponsor
- Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.
- Start
- Feb 2023
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of HTMC0435 in small cell lung cancer (SCLC) (2 arms), sponsored by Shanghai Yidian Pharmaceutical Technology Development Co., Ltd. Primary endpoints: Dose-limiting toxicities, Adverse events and 2 more. Status: unknown.
02
Drugs
HTMC0435
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT05728619.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05728619.